首页> 美国卫生研究院文献>other >Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma
【2h】

Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma

机译:转录因子CCAAT /增强剂结合蛋白α和临界昼夜钟下游靶基因PER2在弥漫性大B细胞淋巴瘤中高度管苏

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Disturbances of circadian rhythms and mammalian clock genes have been implicated in the etiologies of many chronic illnesses, including cancer. We show that transcription factor CCAAT/enhancer-binding protein alpha (C/EBPalpha)-regulated PER2 activation is a potential tumor suppressor pathway in diffuse large B-cell lymphoma (DLBCL), one of the commonest types of mature B-cell lymphoma. Expression analysis of human B-cell lymphoma samples including DLBCL (n = 50), mantle cell (n = 21), follicular (n = 25) and Burkitt (n = 18) lymphoma revealed markedly down-regulated CEBPA and PER2 mRNA levels exclusively in DLBCL samples compared to control lymphatic tissue. We demonstrated direct regulation of the circadian core clock gene PER2 by C/EBPalpha in the pro-B cell line Ba/F3, and forced expression of PER2 resulted in decreased proliferation, GO/G1 cell cycle arrest and increased rates of apoptosis. Interestingly, treatment of human DLBCL cell lines with the histone deacetylase-inhibitor suberoylanilide hydroxamic acid (SAHA) significantly increased the expression of C/EBPalpha and Per2, accompanied by cell growth inhibition; in contrast, siRNA knockdown of CEBPA reduced the anti-proliferative effect of SAHA treatment. Our results show for the first time that C/EBPalpha with its associated direct core clock gene target, PER2, are highly deregulated in DLBCL, suggesting an important tumor suppressive pathway in the pathogenesis of this lymphoma entity.
机译:昼夜节律和哺乳动物钟表基因的骚乱涉及许多慢性疾病的病因,包括癌症。我们表明转录因子CCAAT /增强子结合蛋白α(C / EBPALPHA)-REGUTION的PER2活化是弥漫性大B细胞淋巴瘤(DLBCL)的潜在肿瘤抑制途径,其最初类型的成熟B细胞淋巴瘤之一。在包括DLBCL(n = 50),裂缝细胞(n = 21),卵泡(n = 25)和Burkitt(n = 18)淋巴瘤的人B细胞淋巴瘤样品的表达分析显示出明显下调的CEBPA和Per2 mRNA水平在DLBCL样品中与对照淋巴组织相比。我们证明了在Pro-B细胞系BA / F3中的C / EBPalpha对昼夜核心钟基因PER2的直接调节,并且PER2的强制表达导致增殖降低,GO / G1细胞周期停滞和增加凋亡率。有趣的是,用组蛋白脱乙酰酶抑制剂羟基镁羟肟酸(Saha)的治疗人DLBCL细胞系显着增加了C / EBPALPHA和PER2的表达,伴随着细胞生长抑制作用;相比之下,CEBPA的siRNA敲低降低了SAHA治疗的抗增殖作用。我们的结果表明,C / EBPALPHA与其相关的直接核心时钟基因靶标在DLBCL中高度损失,表明该淋巴瘤实体发病机制中的重要肿瘤抑制途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号